FOXO1 links KRAS G12D and G12V alleles to glutamine and nitrogen metabolism in colorectal cancer.
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Change log
Abstract
Mutations in KRAS, particularly at codon 12, are frequent in adenocarcinomas of the colon, lungs and pancreas, driving carcinogenesis by altering cell signalling and reprogramming metabolism. However, the specific mechanisms by which different KRAS G12 alleles initiate distinctive patterns of metabolic reprogramming are unclear. Using isogenic panels of colorectal cell lines harbouring the G12A, G12C, G12D and G12V heterozygous mutations and employing transcriptomics, metabolomics, and extensive biochemical validation, we characterise distinctive features of each allele. We demonstrate that cells harbouring the common G12D and G12V oncogenic mutations significantly alter glutamine metabolism and nitrogen recycling through FOXO1-mediated regulation compared to parental lines. Moreover, with a combination of small molecule inhibitors targeting glutamine and glutamate metabolism, we also identify a common vulnerability that eliminates mutant cells selectively. These results highlight a previously unreported mutant-specific effect of KRAS alleles on metabolism and signalling that could be potentially harnessed for cancer therapy.
Description
Acknowledgements: AE acknowledges the financial support provided by the CRUK with a multi-disciplinary project award (OncoLive, C54674/A27487), pump-priming funds from the CRUK Cambridge Center (C9685/A25117, C9685/A28397). AE and ARV also acknowledge financial support from Medical Research Council program grants (MC_UU_12022/1 and MC_UU_12022/8). AE also acknowledges funding from the European Union for HORIZON 2022 fLIMAGING3D (101073507) and HILIGHT (101135034, backed by Innovate UK as project number 10107542). CF was funded by the MRC Core award grant MRC_MC_UU_12022/6, and is funded by the CRUK Programme Foundation award C51061/A27453, the H2020 European Research Council Consolidator Grant (ERC819920), and by the Alexander von Humboldt Foundation in the framework of the Alexander von Humboldt Professorship endowed by the Federal Ministry of Education and Research. Work in Simon Cook’s laboratory was supported by Institute Strategic Programme Grants BB/J004456/1, BB/P013384/1 and BB/Y006925/1 from UKRI-BBSRC. We want to thank Dr Laura Tronci (CF group), Dr Pablo Oriol Valls and Dr Andrew Trinh (AE group) for performing experiments in relation to the study of KRAS mutant cell lines that have not been included in this work. We want to thank also Mr Dimitrios Prymidis (CF group) for his invaluable help in the submission of metabolomics data to public repositories. The authors are indebted to the many colleagues in the professional and technical services at the MRC Cancer Unit for making this research possible. Also, the principal investigators express their gratitude towards all members of their respective teams and support staff who endured difficulties related to the COVID lockdowns and the eventual termination of the MRC Cancer Unit.
Keywords
Journal Title
Conference Name
Journal ISSN
1469-3178
Volume Title
Publisher
Publisher DOI
Rights and licensing
Sponsorship
cambridgeuniversity | Cancer Research UK Cambridge Institute, University of Cambridge (CRUK CI) (C9685/A25117,C9685/A28397)
UKRI | Medical Research Council (MRC) (MC_UU_12022/1 and MC_UU_12022/8, MRC_MC_UU_12022/6)
EC | Horizon 2020 Framework Programme (H2020) (101135034 (UKRI #10107542), 101073507)
EC | ERC | HORIZON EUROPE European Research Council (ERC) (ERC819920)
UKRI | Biotechnology and Biological Sciences Research Council (BBSRC) (BB/J004456/1,BB/P013384/1 and BB/Y006925/1)
Alexander von Humboldt-Stiftung (AvH) (n/a)

